



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison

Donald R. Banowit
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaston
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblenz
James J. Pohl
John T. Haran

Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier*
Shameek Ghose
Randall K. Baldwin
Daniel J. Nevirvy
Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras

Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

October 22, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8679
INTERNET ADDRESS:
TSHEA@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1636

Re: U.S. Utility Patent Application
Application No. 10/633,697; Filed: August 5, 2003
For: **Glycosylation Engineering of Antibodies for Improving Antibody-
Dependent Cellular Cytotoxicity**
Inventors: UMAÑA *et al.*
Our Ref: 1975.0010005/TJS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Continued Examination (RCE) Transmittal;
2. Amendment and Reply Under 37 C.F.R. §1.111 and §1.114;
3. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending "Reference" Application;
4. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a "Prior" Patent;
5. Statement Under 37 CFR §3.73(b);
6. Power of Attorney to Prosecute Applications;
7. Second Supplemental Information Disclosure Statement;
8. Form PTO/SB/08A (1 sheet) listing 10 documents (AA2 to AE2 and AL2 to AP2);
9. Form PTO/SB/08B (3 sheets) listing 23 documents (AR55 to AS62); and
10. Copies of cited documents (AL2-AP2 and AR55-AS62).

11. Online Credit Card Payment Authorization in the amount of \$1,250.00 to cover:

\$810.00 Fee for Requested for Continued Examination (RCE);

\$260.00 Fees for two Terminal Disclaimers; and

\$180.00 Fee for Second Supplemental Information Disclosure Statement.


The above-listed documents are being filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Fee payment is provided through online credit card payment. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.
Attorney for Applicants
Registration No. 41,306

TJS/lrd
Enclosures

735126_1.DOC